☆ 4.5 Letter

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

CANCER COMMUNICATIONS (2019)

Get Full Text
Add to Collection

Journal

CANCER COMMUNICATIONS
Volume 39, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s40880-019-0405-5

Keywords

-

Categories

Oncology

Funding

  1. Shanghai Science and Technology Commission [18ZR1423200]
  2. Incubating Program for Clinical Research and Innovation of Renji Hospital [PYXJS16-008]
  3. Shen Kang 3-year action plan program [16CR3062B]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.